Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

EXS74539 · REC-4539

Small molecule · Inhibitor of lysine-specific demethylase 1 (KDM1A) · developed by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals

Phase 1 Most advanced trial
RXRX Developer
1 Registered trials

What is EXS74539?

EXS74539 (REC-4539) is an orally bioavailable, reversible, CNS-penetrant inhibitor of the histone demethylase LSD1 (KDM1A). By blocking LSD1, it alters histone H3K4 and H3K9 methylation, affecting the expression of tumor-related genes. It is being studied in solid tumors, including small cell lung cancer, non-small cell lung cancer, prostate, ovarian, renal, head and neck, hepatic, gastric and triple-negative breast cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
REC-4539
Drug type
Small molecule
Targets
lysine-specific demethylase 1 (KDM1A)
Mechanism
Inhibitor of lysine-specific demethylase 1 (KDM1A)
Pathways
histone H3K4 methylation, histone H3K9 demethylation, tumor suppressor gene expression
Therapy area
Oncology
Developer
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. (RXRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07517198 Phase 1 Solid Tumor Recruiting RXRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Gastric CancerHead and Neck Squamous Cell Carcinoma (HNSCC)Hepatic CancerHigh Grade Neuroendocrine CancerNon-small Cell Lung Cancer (NSCLC)Ovarian CancerProstate CancerRenal Carcinoma (Clear and Non-clear Cell)Small Cell Carcinomas of Non-lung OriginSmall Cell Lung Cancer (SCLC)Solid TumorTriple-negative Breast Cancer (TNBC)

Other drugs acting on KDM1A

More from Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the RXRX page.

Follow RXRX, the company behind EXS74539

See RXRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RXRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.